Ernexa Q2 net loss widens to $4.01 million; reports no revenue

Reuters2026/08/06 22:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ernexa posted a net loss of USD 4.01 million for the quarter ended June 30, 2026, widening from USD 3.14 million a year earlier.
Operating loss widened to USD 4.1 million from USD 2.5 million, as operating expenses climbed 64.1% to USD 4.1 million.
Research and development expense more than doubled to USD 2.79 million, while general and administrative expense edged down 3.88% to USD 1.31 million.
Cash totaled about USD 5 million at June 30, 2026; net cash used in operating activities rose to USD 6.42 million for the six months.
Independently run July 2026 study reproduced earlier ERNA-101 results; IND submission targeted for Q3 2026, Phase 1 trial expected in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036424), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ernexa Q2 net loss widens to $4.01 million; reports no revenue

You may also like

Crypto prices